Prospective Cohort Study Investigating Vaccine-Induced Immune Responses Against Respiratory Viral Infections in Immunocompromised Patients With or Without Hematological Conditions
Led by University of Cologne · Updated on 2026-05-12
1000
Participants Needed
1
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the immune responses to vaccines against respiratory viruses in immunocompromised patients, including those with hematological or oncological conditions. These patients often have weakened immune systems due to disease or treatment, making them more vulnerable to severe respiratory infections from viruses like influenza, RSV, and coronaviruses. The study aims to better understand how vaccine-induced immunity, especially T cell responses, functions in these patients, as current data mostly focuses on antibody responses which may be less effective in this group.
This observational study will analyze early and late booster vaccinations in immunocompromised patients who are vaccinated as part of routine care. It will focus on measuring virus-specific T cell responses and humoral immune responses over time. The research will gather blood samples and other data to assess the cellular and antibody responses to vaccination, helping to fill knowledge gaps about long-term protection in this vulnerable population.
Participants will be monitored for up to 12 months after vaccination to evaluate humoral and cellular immune responses, including seroconversion. The study will collect and analyze samples at various points to measure these immune markers. The University of Cologne leads this research, which seeks to improve understanding of vaccine effectiveness and guide better preventive strategies for immunocompromised patients facing respiratory viral infections.
CONDITIONS
Brief Title
Vaccine-induced Immunity in Immunocompromised Patients
Research Team
S
Sibylle Mellinghoff, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with immunosuppression caused by treatment or underlying diseases
Patients who have been vaccinated or are willing to be vaccinated against respiratory virus infections according to current recommendations
Age 18 years or older
You will not qualify if you...
Patients unwilling or ineligible for vaccination under current recommendations
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance
Duration - 12 months
Participants who undergo routine vaccination and care are observed for immune responses to respiratory virus vaccines.
Multiple visits for sample collection and immune response assessments
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase II Study Evaluating Allogeneic Hematopoietic Stem Cell Transplantation
for Adults With VEXAS Syndrome
Including Reduced Intensity Conditioning Regimens and GVHD Prophylaxis
Evaluating Allogeneic Hematopoietic Stem Cell Transplantation
for Patients with GATA2 Mutations or MonoMAC Syndrome
Using Different Donor Types and Conditioning Regimens
Study on Clozapines Immune Effects in Parkinsons Disease Patients with Psychosis
Genetic Study to Understand Immune Disorders and Their Impact on Families
Evaluating PCR Testing to Improve Antibiotic Use in Immunocompromised Adults with Suspected Ventilator-Associated or Hospital-Acquired Pneumonia on Mechanical Ventilation
Optimizing Antiviral Treatment with Paxlovid and Remdesivir in Immunocompromised Adults with Mild to Moderate COVID-19
Optimizing Combination and Duration of Antiviral Therapy in Immunocompromised Patients with COVID-19 The OPTICOV Randomized Controlled Trial
Phase 12 Study of CD45RA Depleted Stem Cell Addback to Reduce Viral and Fungal Infections After Alternative Donor TCRabCD19 Depleted Hematopoietic Stem Cell Transplant in Patients Up to 25 Years
Comprehensive Study of Immune Dysregulation Across All Ages
Including Patients and Healthy Controls in Sweden
Prospective Cohort Study Investigating Vaccine-Induced Immune Responses Against Respiratory Viral Infections in Immunocompromised Patients With or Without Hematological Conditions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Investigation of Vaccine-Induced Immune Response After Vaccination Against Respiratory Viruses in Immunocompromised Patients With or Without Hemato-Oncological Diseases (RESPONSE): Protocol for a Prospective Cohort Study.
Eloísa Felipe Fumero, Jannik Stemler, Rosanne Sprute...